1. Heterosubtypic Antibodies to Influenza A Virus Have Limited Activity against Cell-Bound Virus but Are Not Impaired by Strain-Specific Serum Antibodies.

    Journal of Virology 89(6):3136 (2015) PMID 25552718

    The majority of influenza virus-specific antibodies elicited by vaccination or natural infection are effective only against the eliciting or closely related viruses. Rare stem-specific heterosubtypic monoclonal antibodies (hMAbs) can neutralize multiple strains and subtypes by preventing hemaggl...
  2. Heterosubtypic antibodies to influenza A virus have limited activity against cell-bound virus but are not impaired by strain-specific serum antibodies.

    Journal of Virology 89(6):3136 (2015) PMID 25552718 PMCID PMC4337524

    The majority of influenza virus-specific antibodies elicited by vaccination or natural infection are effective only against the eliciting or closely related viruses. Rare stem-specific heterosubtypic monoclonal antibodies (hMAbs) can neutralize multiple strains and subtypes by preventing hemaggl...
  3. Prevalence and predictors for homo- and heterosubtypic antibodies against influenza a virus.

    Clinical Infectious Diseases 59(10):1386 (2014) PMID 25139962

    The effectiveness of trivalent influenza vaccination has been confirmed in several studies. To date, it is not known whether repeated exposure and vaccination to influenza promote production of cross-reactive antibodies. Furthermore, how strains encountered earlier in life imprint the immune res...
  4. Prevalence and predictors for homo- and heterosubtypic antibodies against influenza a virus.

    Clinical Infectious Diseases 59(10):1386 (2014) PMID 25139962

    The effectiveness of trivalent influenza vaccination has been confirmed in several studies. To date, it is not known whether repeated exposure and vaccination to influenza promote production of cross-reactive antibodies. Furthermore, how strains encountered earlier in life imprint the immune res...
  5. Prevalence and predictors for homo- and heterosubtypic antibodies against influenza a virus.

    Clinical Infectious Diseases 59(10):1386 (2014) PMID 25139962

    The effectiveness of trivalent influenza vaccination has been confirmed in several studies. To date, it is not known whether repeated exposure and vaccination to influenza promote production of cross-reactive antibodies. Furthermore, how strains encountered earlier in life imprint the immune res...
  6. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody.

    Journal of Virology 88(12):7083 (2014) PMID 24719426 PMCID PMC4054347

    A human monoclonal heterosubtypic antibody, MAb 3.1, with its heavy chain encoded by VH3-30, was isolated using phage display with immobilized hemagglutinin (HA) from influenza virus A/Japan/305/1957(H2N2) as the target. Antibody 3.1 potently neutralizes influenza viruses from the H1a clade (i.e...
  7. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody.

    Journal of Virology 88(12):7083 (2014) PMID 24719426 PMCID PMC4054347

    A human monoclonal heterosubtypic antibody, MAb 3.1, with its heavy chain encoded by VH3-30, was isolated using phage display with immobilized hemagglutinin (HA) from influenza virus A/Japan/305/1957(H2N2) as the target. Antibody 3.1 potently neutralizes influenza viruses from the H1a clade (i.e...
  8. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody.

    Journal of Virology 88(12):7083 (2014) PMID 24719426 PMCID PMC4054347

    A human monoclonal heterosubtypic antibody, MAb 3.1, with its heavy chain encoded by VH3-30, was isolated using phage display with immobilized hemagglutinin (HA) from influenza virus A/Japan/305/1957(H2N2) as the target. Antibody 3.1 potently neutralizes influenza viruses from the H1a clade (i.e...
  9. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

    PLoS Pathogens 9(1):e1003106 (2013) PMID 23300456 PMCID PMC3536657

    Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bNAbs) although they express the epitopes recognized by bNAbs to the HIV envelope glycoprotein (Env). To understand whether and how Env immunogens interact with the predicted germline versions of kn...
  10. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

    PLoS Pathogens 9(1):e1003106 (2013) PMID 23300456 PMCID PMC3536657

    Vaccine candidates for HIV-1 so far have not been able to elicit broadly neutralizing antibodies (bNAbs) although they express the epitopes recognized by bNAbs to the HIV envelope glycoprotein (Env). To understand whether and how Env immunogens interact with the predicted germline versions of kn...
  11. Anti-HIV B Cell lines as candidate vaccine biosensors.

    Journal of Immunology 189(10):4816 (2012) PMID 23066156 PMCID PMC3626558

    Challenge studies following passive immunization with neutralizing Abs suggest that an HIV vaccine could be efficacious were it able to elicit broadly neutralizing Abs (bNAbs). To better understand the requirements for activation of B cells producing bNAbs, we generated cell lines expressing bNA...
  12. Anti-HIV B Cell lines as candidate vaccine biosensors.

    Journal of Immunology 189(10):4816 (2012) PMID 23066156 PMCID PMC3626558

    Challenge studies following passive immunization with neutralizing Abs suggest that an HIV vaccine could be efficacious were it able to elicit broadly neutralizing Abs (bNAbs). To better understand the requirements for activation of B cells producing bNAbs, we generated cell lines expressing bNA...
  13. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

    Nature Medicine 15(8):951 (2009) PMID 19525965

    Neutralizing antibodies are thought to be crucial for HIV vaccine protection, but studies in animal models suggest that high antibody concentrations are required. This is a major potential hurdle for vaccine design. However, these studies typically apply a large virus inoculum to ensure infectio...
  14. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

    Nature Medicine 15(8):951 (2009) PMID 19525965

    Neutralizing antibodies are thought to be crucial for HIV vaccine protection, but studies in animal models suggest that high antibody concentrations are required. This is a major potential hurdle for vaccine design. However, these studies typically apply a large virus inoculum to ensure infectio...
  15. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

    Nature Medicine 15(8):951 (2009) PMID 19525965 PMCID PMC4334439

    Neutralizing antibodies are thought to be crucial for HIV vaccine protection, but studies in animal models suggest that high antibody concentrations are required. This is a major potential hurdle for vaccine design. However, these studies typically apply a large virus inoculum to ensure infectio...
  16. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

    Nature Medicine 15(8):951 (2009) PMID 19525965 PMCID PMC4334439

    Neutralizing antibodies are thought to be crucial for HIV vaccine protection, but studies in animal models suggest that high antibody concentrations are required. This is a major potential hurdle for vaccine design. However, these studies typically apply a large virus inoculum to ensure infectio...
  17. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

    PLoS Pathogens 5(5):e1000433 (2009) PMID 19436712 PMCID PMC2674935

    Developing an immunogen that elicits broadly neutralizing antibodies (bNAbs) is an elusive but important goal of HIV vaccine research, especially after the recent failure of the leading T cell based HIV vaccine in human efficacy trials. Even if such an immunogen can be developed, most animal mod...
  18. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

    PLoS Pathogens 5(5):e1000433 (2009) PMID 19436712 PMCID PMC2674935

    Developing an immunogen that elicits broadly neutralizing antibodies (bNAbs) is an elusive but important goal of HIV vaccine research, especially after the recent failure of the leading T cell based HIV vaccine in human efficacy trials. Even if such an immunogen can be developed, most animal mod...
  19. Recombination of retrotransposon and exogenous RNA virus results in nonretroviral cDNA integration.

    Science 323(5912):393 (2009) PMID 19150848

    Retroviruses have the potential to acquire host cell-derived genetic material during reverse transcription and can integrate into the genomes of larger, more complex DNA viruses. In contrast, RNA viruses were believed not to integrate into the host's genome under any circumstances. We found that...
  20. Recombination of retrotransposon and exogenous RNA virus results in nonretroviral cDNA integration.

    Science 323(5912):393 (2009) PMID 19150848

    Retroviruses have the potential to acquire host cell-derived genetic material during reverse transcription and can integrate into the genomes of larger, more complex DNA viruses. In contrast, RNA viruses were believed not to integrate into the host's genome under any circumstances. We found that...